Document:

ex10x1x1.htm

    Exhibit 10.1.1

     

    
      ASPENBIO
PHARMA, INC.

       

      AMENDMENT
TO 2002 STOCK INCENTIVE PLAN

       

      EFFECTIVE
JUNE 9, 2008

       

      This
Amendment No. 1, dated and effective June 9, 2008 (the “Amendment”), is an
amendment to the 2002 Stock Incentive Plan, as amended and restated on June 1,
2007 (the “Plan”) of AspenBio Pharma, Inc., a Colorado corporation (the
“Company”).  All capitalized terms used in this Amendment without
definition have the meanings set forth in the Plan.

       

      WHEREAS,
Section 20(a) authorizes the Board of Directors of the Company to make
amendments to the Plan, subject to shareholder approval as required by law or
agreement.

       

      WHEREAS,
on March 27, 2008, the Board approved an amendment to the Plan to increase the
number of shares available for awards under the Plan from 4,250,000 to
4,600,000, and submitted such amendment to the Company’s shareholders for
approval at the annual meeting of shareholders held on June 9,
2008.

       

      WHEREAS,
on June 9, 2008, the shareholders approved the foregoing amendment to the
Plan.

       

      NOW,
THEREFORE, intending to be legally bound, and in accordance with the approvals
set forth in the WHEREAS clauses, which are incorporated by reference into this
Amendment, the Company amends the Plan as follows:

       

      1.           Section
4 of the Plan is deleted in it entirety and is replaced by the
following:

       

      “4.           The Common
Stock.  The Board is authorized to appropriate, issue and sell
for the purposes of the Plan, and the Option Committee is authorized to grant
Options and Rights to Purchase with respect to, a total number, not in excess of
4,600,000 shares of Common Stock, either treasury or authorized but unissued or
the number and kind of shares of stock or other securities which in accordance
with Section 16 of this Plan shall be substituted for the 4,600,000 shares or
into which such 4,600,000 shares shall be adjusted.  All or any unsold
shares subject to an Option or Right to Purchase that for any reason expires or
otherwise terminates may again be made subject to Options or Rights to Purchase
under the Plan.  No person may be granted Options or Rights to
Purchase under this Plan covering in excess of an aggregate of 500,000 Option
Shares and shares of Restricted Stock in any calendar year, subject to
adjustments in connection with Section 16 of this Plan.”

       

      2.           Except
as amended by this Amendment, the Plan continues in full force and
effect.

       

      3.           In
the event of a conflict between this Amendment and the Plan, this Amendment
shall govern.ex10x1x2.htm

    Exhibit 10.1.2

     

    
      ASPENBIO
PHARMA, INC.

       

      AMENDMENT
TO 2002 STOCK INCENTIVE PLAN

       

      EFFECTIVE
NOVEMBER 20, 2009

       

      This
Amendment No. 2, dated and effective November 20, 2009 (the “Amendment”) is an
amendment to the 2002 Stock Incentive Plan, as amended and restated on June 1,
2007 (the “Plan”) of AspenBio Pharma, Inc., a Colorado corporation (the
“Company”).  All capitalized terms used in this Amendment without
definition have the meanings set forth in the Plan.

       

      WHEREAS,
Section 20(a) authorizes the Board of Directors of the Company to make
amendments to the Plan, subject to shareholder approval as required by law or
agreement.

       

      WHEREAS,
on September 18, 2009, the Board approved an amendment to the Plan to increase
the number of shares available for awards under the Plan from 4,600,000 to
6,100,000, and submitted such amendment to the Company’s shareholders for
approval at the annual meeting of shareholders held on November 20,
2009.

       

      WHEREAS,
on November 20, 2009, the shareholders approved the foregoing amendment to the
Plan.

       

      NOW,
THEREFORE, intending to be legally bound, and in accordance with the approvals
set forth in the WHEREAS clauses, which are incorporated by reference into this
Amendment, the Company amends the Plan as follows:

       

      1.           Section
4 of the Plan is deleted in it entirety and is replaced by the
following:

       

      “4.           The Common
Stock.  The Board is authorized to appropriate, issue and sell
for the purposes of the Plan, and the Option Committee is authorized to grant
Options and Rights to Purchase with respect to, a total number, not in excess of
6,100,000 shares of Common Stock, either treasury or authorized but unissued or
the number and kind of shares of stock or other securities which in accordance
with Section 16 of this Plan shall be substituted for the 6,100,000 shares or
into which such 6,100,000 shares shall be adjusted.  All or any unsold
shares subject to an Option or Right to Purchase that for any reason expires or
otherwise terminates may again be made subject to Options or Rights to Purchase
under the Plan.  No person may be granted Options or Rights to
Purchase under this Plan covering in excess of an aggregate of 500,000 Option
Shares and shares of Restricted Stock in any calendar year, subject to
adjustments in connection with Section 16 of this Plan.”

       

      2.           Except
as amended by this Amendment, the Plan continues in full force and
effect.

       

      3.           In
the event of a conflict between this Amendment and the Plan, this Amendment
shall govern.ex10x4x1.htm

    Exhibit 10.4.1

     

     

    
      

       

      SETTLEMENT AND RELEASE
AGREEMENT

       

      

      This
Settlement and Release Agreement (“Settlement Agreement”) is made this December
31, 2009, by and between Merial
Limited, a company limited by shares registered in England and Wales
(registered number 3332751), with a registered office at P.O. Box 327,
Sandringham House, Sandringham Avenue, Harlow Business Park, Harlow, Essex CM19
5QA, England, and domesticated in Delaware, USA, as Merial LLC with a place of
business at 3239 Satellite Boulevard, Duluth, Georgia 30096-4640 (“Merial”), and
AspenBio Pharma, Inc.,
(formerly known as “AspenBio, Inc.) with an address of 1585 South Perry Street,
Castle Rock, CO 80104 (“AspenBio”).

      

      WITNESSETH:

      

      WHEREAS, on March 29, 2003,
Merial and AspenBio (collectively, the “Parties”) entered into a Distribution
Agreement wherein AspenBio agreed to develop a Product and Merial agreed to
market, distribute, and sell the Product (the “Distribution
Agreement”).  All “defined” terms used in this Settlement Agreement
shall have the definition provided for in the Distribution Agreement;
and

      

      WHEREAS, AspenBio has been
unable to successfully develop the Product and has discontinued all development
efforts on the Product; and

      

      WHEREAS, Merial desires that
AspenBio not attempt to develop the Product with any third parties;
and

      

      WHEREAS, it is the desire of
the Parties to terminate the Distribution Agreement and to settle, once and
forever, all claims arising from or relating to the Distribution Agreement, and
to release each other from any liability arising from or relating to the
Distribution Agreement; and

      

      NOW, THEREFORE, in
consideration of the mutual agreements, covenants, and releases, and other good
and valid consideration as set forth herein, the receipt and sufficiency of
which are hereby acknowledged by each of the Parties, the Parties do hereby
covenant, represent, warrant, promise, and agree to the following:

      

      
        	
                1.

              	
                PAYMENT.  On or
      before January 31, 2010, AspenBio shall pay Merial FIFTY THOUSAND DOLLARS
      ($50,000) in good funds (certified or cashier’s check) pursuant to
      Sections 6.3(b) and 1.2 of the Distribution Agreement.  The
      payment must be delivered to the following
  address:

              

      

      

      Merial
Limited

      Attn:
Adam C. Bassing

      3239
Satellite Blvd.

      Duluth,
GA 30096

      

      
        	
                2.

              	
                TERMINATION
      OF LICENSE AGREEMENTS.

              

      

      

      AspenBio
shall terminate all agreements associated with the Distribution Agreement that
provide it with any intellectual property or contractual rights to the
intellectual property underlying the Product, including without limitation, all
license agreements with universities.

       

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

      
 

      
        	
                3.

              	
                ASPENBIO’S
      REPRESENTATIONS AND WARRANTIES.

              

      

      

      AspenBio
represents and warrants that it will not conduct any activities related to the
development of the Product, for a period of five (5) years from the date of this
Settlement Agreement, whether such activities are conducted independently, with
any affiliate or with any third party.

      

      
        	
                4.

              	
                TERMINATION
      OF THE DISTRIBUTION AGREEMENT.

              

      

      

      Upon full
and complete performance by AspenBio of the conditions contained in Paragraphs
1, 2 and 3, the Distribution Agreement shall terminate.

      
        

        
          	
                  5.

                	
                  

                    MUTUAL
      RELEASES.

                  

                

        

         

      

      
        	
                (a)  

              	
                AspenBio
      hereby releases and forever discharges Merial, its affiliates, directors,
      officers, shareholders, agents, representatives, and employees, and their
      successors and assigns, from any and all claims, cause or causes of
      action, damages, claims for costs, attorneys’ fees, losses, or demands
      arising out of or in any way related to the Distribution
      Agreement.

              

      

      

      
        	
                (b)  

              	
                Upon
      the full and complete performance by AspenBio of the conditions contained
      herein, Merial shall release and forever discharge AspenBio, its
      affiliates, directors, officers, shareholders, agents, representatives,
      and employees, and their successors and assigns, from any and all claims,
      cause or causes of action, damages, claims for costs, attorneys’ fees,
      losses or demands arising out of or in any way related to the Distribution
      Agreement.

              

      

      

      
        	
                6.

              	
                DEFAULT.  If any of
      the following events occur, AspenBio will be in breach of this Settlement
      Agreement:

              

      

      

      
        	
                (c)  

              	
                AspenBio
      fails to make the $50,000 payment to Merial in good funds on or before
      January 31, 2010, as set forth in Paragraph 1
  hereof;

              

      

      

      
        	
                (d)  

              	
                AspenBio
      fails to terminate all agreements referenced in Paragraph 2 hereof;
      or

              

      

      

      
        	
                (e)  

              	
                AspenBio
      conducts any activities related to the development of the Product as set
      forth in Paragraph 3 hereof.

              

      

      

      In the
event AspenBio breaches this Settlement Agreement, Merial shall be entitled to
take any and all legal action available against AspenBio, including without
limitation, an action for breach of this Settlement Agreement for the full
amounts due and owing to Merial hereunder.

      

      
        	
                7.

              	
                NO
      ASSIGNMENT.  The Parties
      warrant and represent that there has been no assignment, sale, grant,
      conveyance or transfer, by operation of law or otherwise, to any other
      person, firm, corporation or entity of any claim, demand, right, cause of
      action or interest released in this Settlement Agreement.  The
      Parties agree to indemnify, defend and hold each other harmless from any
      claim, liability, or expense which may be incurred as a result of the
      assertion of any claim, right, or interest by any person by reason of any
      such assignment, sale or transfer.

              

      

       

       

      
 

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

      
        	
                8.

              	
                ENTIRE
      AGREEMENT.  This
      Settlement Agreement constitutes the sole and entire agreement and
      understanding of the Parties with respect to the subject matter hereof and
      no representations, terms or agreements other than those set forth herein
      have been relied upon or shall be binding upon any of the
      Parties.  The terms of this Settlement Agreement are contractual
      and not mere recitals.

              

      

      

      
        	
                9.

              	
                SEVERABILITY.  If any term
      or condition of this Settlement Agreement or application thereof to any
      person, entity or circumstance shall, to any extent, be invalid or
      unenforceable, neither the remainder of this Settlement Agreement nor the
      application thereof shall be affected thereby; and each remaining term or
      condition of this Settlement Agreement shall be valid and enforceable to
      the fullest extent permitted by law, and shall continue to inure to the
      benefit of and be binding upon the
Parties.

              

      

      

      
        	
                10.

              	
                AMENDMENTS.  The terms
      of this Settlement Agreement shall not be altered, amended, modified or
      otherwise changed in any respect or particular except by a writing duly
      executed by authorized representatives of the Parties.  The
      Parties hereby acknowledge and agree that they will make no claim at any
      time that the terms of this Settlement Agreement have been orally altered
      or modified in any respect
whatsoever.

              

      

      

      
        	
                11.

              	
                WARRANTY
      OF AUTHORITY.  Each Party
      represents and warrants to the other Party that it has the power and
      authority to execute and deliver this Settlement Agreement, that it has
      obtained all necessary authorizations to enter into this Settlement
      Agreement, that the execution of this Settlement Agreement does not put it
      in violation of any agreement to which it is a party, and that this
      Settlement Agreement constitutes a legal, valid and binding obligation
      enforceable upon the Parties in accordance with its
  terms.

              

      

      

      
        	
                12.

              	
                NO
      REPRESENTATION.  The Parties
      hereby represent that they have carefully read this Settlement Agreement
      and know the contents thereof, and sign the same as their own free act
      without any promise, inducement, or representation not fully expressed
      herein.

              

      

      

      
        	
                13.

              	
                REPRESENTATION
      BY COUNSEL.  The Parties
      further acknowledge that they have been represented by counsel of their
      own choosing in connection with this Settlement Agreement and that the
      Settlement Agreement was negotiated at arm’s length.  The
      Parties agree that this Settlement Agreement shall not be construed for or
      against any Party by reason of that Party having drafted or negotiated, or
      failed to draft or negotiate, all or any portion of any provision of this
      Settlement Agreement.

              

      

      

      
        	
                14.

              	
                NO
      WAIVER.  Neither the
      failure of either Party to exercise any power given such Party herein or
      to insist upon strict compliance by the other Party with its obligations
      hereunder, nor any custom or practice of the Parties at variance with the
      terms hereof shall constitute a waiver of either Party’s right to demand
      exact compliance with the terms
hereof.

              

      

      

      
        	
                15.

              	
                WAIVER
      OF JURY TRIAL.  To the
      extent permitted by law, AspenBio and Merial hereby knowingly,
      voluntarily, and intentionally waive any right they may have to a trial by
      jury with respect to any litigation based hereon, or arising out of,
      under, or in connection with this Settlement
  Agreement.

              

      

      

      
        	
                16.

              	
                CHOICE
      OF LAW.  This
      Settlement Agreement shall be governed by the laws of the State of
      Georgia.

              

      

       

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

      
 

      
        	
                17.

              	
                SECTION
      HEADINGS.  The
      headings used in this Settlement Agreement are for convenience only and in
      no way define, limit or describe the scope or intent of any provisions or
      sections of this Settlement
Agreement.

              

      

      

      
        	
                18.

              	
                DUPLICATE
      ORIGINALS.  Each of the
      undersigned hereby represents, covenants, and warrants that this
      Settlement Agreement may, for convenience, be executed by the Parties in
      duplicate originals, each of which contains the entire agreement of the
      Parties and is intended to be and is as valid and binding as its
      counterpart original.

              

      

      

      IN WITNESS WHEREOF, the Parties hereto
have caused this Settlement Agreement to be executed by their duly authorized
representatives.

      

       

      
        	

                MERIAL
      LIMITED

              	
                

                  ASPENBIO
      PHARMA, INC.

                

                 

              
	
                By:
      ­­­/s/ Mark Morrison

                 

              	
                By:
      /s/ Jeffrey
      McGonegal

                 

              
	
                Name:
      Mark Morrison

                 

              	
                Name:
      Jeffrey McGonegal

                 

              
	
                Title:
      VP

                 

              	
                Title:
      CFO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]